Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,355 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05557578RecruitingPhase 2
New drug before surgery for resectable bile duct cancer
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Hangzhou, ZhejiangAges 18–75 - NCT05559879RecruitingPhase 1/Phase 2
Cabozantinib and dostarlimab for recurrent gynecologic carcinosarcoma
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
Birmingham, AlabamaAges 18 years+ - NCT05562830RecruitingPhase 1/Phase 2
Study for bladder or urinary tract cancer after PD-1 failure
This Phase 1/2 study tests investigational cancer treatment(s) in people with locally advanced or metastatic urothelial cancer that has not responded to PD-1/PD-L1 immunotherapy. It may help by trying a new approach after prior checkpoint treatment has stopped working or the cancer returns.
Orange, CaliforniaAges 18 years+ - NCT05568680RecruitingPhase 1
Early trial of SynKIR-110 for certain ovarian and lung-lining cancers
This Phase 1 study tests SynKIR-110 in people with certain advanced cancers that have come back or continued growing after prior treatments. It aims to find out if the treatment is safe and how the body responds, including early signs of effectiveness.
Tampa, FloridaAges 18 years+ - NCT05570253RecruitingPhase 2
SDX-7320 plus eribulin for metastatic triple-negative breast cancer
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Miami, FloridaAges 18 years+ - NCT05582122RecruitingPhase 2
Tracking HPV16 DNA in blood to spot cancer coming back
This study checks whether a blood test for HPV16 DNA can predict when HPV-related throat cancer comes back after treatment. It may help improve follow-up care by catching recurrence earlier.
Saint-Denis, La RéunionAges 18 years+ - NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT05588648RecruitingPhase 1/Phase 2
Testing vactosertib for osteosarcoma that keeps coming back
This Phase 1/2 study tests how safe and how well vactosertib works for adolescents and adults with osteosarcoma that has returned, stopped responding, or is getting worse despite prior treatment. You may be able to join if you meet age, cancer, recovery-from-prior-therapy, and health-test requirements.
Cleveland, OhioAges 12 years+ - NCT05592886Recruiting
Oral probiotic-and-prebiotic drink to prevent colon polyps returning
This study tests whether an oral synbiotic (a probiotic plus a prebiotic) can reduce the chance that advanced colon growths come back after they were removed. It also looks at changes in stool-related bacterial “gene markers” that may signal lower risk over time.
Hohhot, Inner MongoliaAges 18–90 - NCT05594095RecruitingPhase 2
Study for advanced ER+ HER2− breast cancer after CDK4/6 therapy
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05594368RecruitingPhase 1
Test targeted radiation to treat recurrent ventricular tachycardia
This trial studies a radiation approach (called stereotactic body radiation therapy, or SBRT) to treat ventricular tachycardia (a dangerous heart rhythm) that keeps coming back. It aims to reduce the rhythm episodes in people who have already tried catheter ablation (a procedure to cauterize rhythm sources) or cannot have it.
OstravaAges 18 years+ - NCT05595590RecruitingPhase 2
Radiation plus immunotherapy for recurrent head and neck cancer
This study tests whether adding an immunotherapy medicine called tislelizumab to radiation can better control recurrent (coming back) head and neck squamous cell cancer. It is aimed at people whose cancer can’t be fully removed by surgery or can’t be safely removed.
Chengdu, SichuanAges 18–75 - NCT05607407RecruitingPhase 2
Methimazole for progressive glioblastoma after planned surgery
This Phase 2 trial studies whether methimazole, a medicine that affects the thyroid system, can help control progressive glioblastoma (a fast-growing brain tumor) after surgery. It looks at safety and how well the treatment works when given after your surgical plan.
Cleveland, OhioAges 18 years+ - NCT05610501Recruiting
Ultrasound-guided biopsy for pelvic masses
This study looks at how well an ultrasound-guided needle biopsy (Tru-Cut) can safely collect tissue samples from pelvic masses. It may help doctors confirm diagnoses and guide treatment by improving how biopsies are done in real-world care.
LeuvenAges 18 years+ - NCT05621668RecruitingPhase 1
First drug trial using engineered T-cells for sarcoma
This Phase 1 trial tests a new immune therapy made from your T-cells and engineered to target sarcoma tumors. It is designed to see if the treatment is safe and whether it can shrink advanced or metastatic soft tissue or bone sarcoma.
Houston, TexasAges 12 years+ - NCT05622409Recruiting
Tissue and genetic data registry for diffuse glioma in adults
This study collects tumor tissue and basic medical information to better understand the genes involved in adult diffuse glioma. It may help future treatments by building a detailed research database and matching patients to study arms.
Kaohsiung CityAges 20 years+ - NCT05627232RecruitingPhase 1
Tazemetostat and palbociclib for relapsed or resistant AML
This early-phase study tests whether tazemetostat and palbociclib can help people with acute myeloid leukemia (AML) that has come back or did not respond to treatment. It looks for safety and early signs of how well the treatment works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05631249RecruitingPhase 2
Sotorasib for KRAS G12C lung cancer after prior treatments
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
LyonAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+ - NCT05638841Recruiting
Study of repeat atrial fibrillation risk after ablation
This study follows adults who have had a procedure to treat an irregular heartbeat, to understand who is more likely to have it return. It may help doctors predict risk and plan follow-up after the procedure.
BeijingAges 18 years+ - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Daphne, AlabamaAges 18 years+ - NCT05650619Recruiting
Study of return of kidney disease after transplant
This observational study looks at people with FSGS or minimal change disease whose kidney disease came back after a transplant. The goal is to better understand patterns of recurrence and what factors may be linked to it.
Ann Arbor, MichiganAges Any age - NCT05657873RecruitingPhase 2
Targeted radiation for metastatic lung cancer with liver spread
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Miami, FloridaAges 18 years+ - NCT05658081Recruiting
Two surgical stitch methods for Crohn’s bowel surgery
This trial compares two surgical ways of connecting the bowel in people with Crohn’s disease who need bowel resection (removal of a diseased bowel segment) and then reconnect it. If you qualify, the study may help show which method is safer or leads to better recovery.
Nanjing, JiangsuAges 16–60
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,355 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.